Tylenol Arthritis Caplet voluntary recall expanded

Dec 29, 2009

(AP) -- Johnson & Johnson is expanding a voluntary recall of Tylenol Arthritis Caplets due to consumer reports of a moldy smell that can cause nausea and sickness.

According to a statement posted to the Food and Drug Administration Web site late Monday, the New Brunswick, N.J., company is now recalling all product lots of the Pain Caplet 100 count bottles with the red EZ-Open Cap.

Johnson & Johnson had recalled five lots of the product last month after consumers complained of a musty, mildew-like odor that triggered nausea, stomach pain, vomiting and diarrhea.

The health care company said the odor results from trace amounts of a chemical called 2,4,6-tribromoanisole. That chemical is believed to result from the breakdown of another chemical used to treat wooden pallets that transport and store packaging materials.

To date, the side effects, which also include vomiting and diarrhea, have been "temporary and non-serious," although the health effects of the compound have not been studied.

The only affects the specific lots cited. All other Arthritis pain products remain available.

The company will reintroduce Tylenol Arthritis Pain Caplets 100 count by January after moving production to a new facility.

J&J's McNeil consumer health care division sells a range of over-the-counter medicines, including cold reliever Sudafed and the antacid Mylanta. The unit posted $16 billion in sales in 2008, according to J&J's annual report.

Consumers seeking a refund or replacement can call J&J at 1-888-222-6036.

Company shares rose 38 cents to $65.32 in morning trading Tuesday.

Explore further: Hormonal therapy for transsexualism safe and effective

5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

J&J recalls infants', children's liquid Tylenol

Sep 25, 2009

(AP) -- Johnson & Johnson's McNeil unit said Thursday it is voluntarily recalling 57 lots of infants' and children's liquid Tylenol products because of possible bacterial contamination.

Baxter issues urgent recall of Heparin

Jan 26, 2008

Baxter Healthcare has issued an urgent U.S. recall of nine lots of the injectable blood thinner heparin after reports of adverse patient reactions.

FDA panel to vote on painkiller restrictions

Jun 30, 2009

(AP) -- Government experts are scheduled to vote on whether Nyquil and other combination cold medications should be pulled from the market to help curb deadly overdoses.

Recommended for you

Hormonal therapy for transsexualism safe and effective

18 hours ago

Hormonal therapy for transsexual patients is safe and effective, a multicenter European study indicates. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.

Royalty Pharma lets Elan takeover bid expire

22 hours ago

Royalty Pharma has let its latest takeover bid for Irish drugmaker Elan lapse as it decided against pressing ahead with a court challenge of a requirement that it withdraw the offer.

FDA approves new silicone breast implants

Jun 17, 2013

(HealthDay)—MemoryShape breast implants have been approved by the U.S. Food and Drug Administration for breast augmentation in women 22 and older, and for breast reconstruction, the FDA said Friday.

User comments : 0

More news stories

Finding the way to lung tumours by 'GPS'

The innumerable divisions of the bronchi often turn the hunt for tumours in the lungs into a game of chance. But soon, lung specialists will be able to navigate accurately inside the airways by "GPS".

Diabetes key to transplant success, research finds

(Medical Xpress)—Better management of diabetes could dramatically improve outcomes for lung transplant patients, with new research showing that those without diabetes lived twice as long as transplant recipients ...

DNA constructs antenna for solar energy

Researchers at Chalmers University of Technology have found an effective solution for collecting sunlight for artificial photosynthesis. By combining self-assembling DNA molecules with simple dye molecules, ...

Seeing data

More data are being created, consumed, and transported than ever before, and in all areas of society, including business, government, health care, and science. The hope and promise is that this influx of ...